Introduction: Symptoms of adenoid hypertrophy is commonly seen among the pediatric age group. Since the surgical approach for this on immunity is controversial, the study was planned out to appraise the outcome of intranasal Fluticasone Furoate spray use.
Introduction
The adenoid (PHARYNGEAL or Luschka's tonsil) forms part of Waldeyer's ring of lymphoid tissue at the portal of upper respiratory tract. In early childhood this is the first site of immunological contact for inhaled antigen 1 .In about six months to one year of life,the nasopharyngeal tonsil becomes evident; it gets larger in size during the first 6 to 8 years of life and generally shrinks by adolescence. Even though the etiology behind adenoid hypertrophy (AH) is unclear, frequent infection, allergy, rhinitis and chronic sinusitis are commonly perceived as important causes 2 . Historically the adenoid has been associated with upper airway obstruction, as a focus of sepsis & more recently with the persistence of otitis media with effusion (OME). An untreated AH may even lead to behavior alterations, low growth & weight gain, craniofacial alterations secondary to mouth breathing, mastication and swallowing disorders, accompanied by corpulmonale and left heart failure 3 . Thus adenoidectomy is currently considered as the typical management strategy for children with severe symptoms caused by AH, although some study suggests that more conservative treatments using topical, intranasally administered steroid preparations may have significant improvement 4-7 in less serious cases. Herein the study is planned to see the clinical efficacy of Intranasal Spray(INS) Fluticasone Furoate in reducing enlarged adenoid in children.
Methods
The study was a prospective observational study. Sixty four patients (42 males, 22 females) ranging from 4 to 15 year old who visited the outpatient department of Otolaryngology Department with the complaints of snoring and nasal obstruction were selected between April 2017 to August 2017, with inclusion and exclusion criteria stated below, patients were selected and briefed about the study with written consent from the parents or legal guardians. All the data gathered was presented as mean ± standard deviation. Data was analyzed by appropriate parametric (Paired t-test) test. (p<0.05) was considered as statistically significant improvement.
Results
Out of 1120 children attending the outpatient department of the tertiary hospital, 75 had adenoid hypertrophy, giving a prevalence of 6.69% (Figure 1 ). Among the 75 patients 64 completed the due course of treatment by INS fluticasone furoate over the 4weeks regimen.3 parents discontinued due to non-cooperation by the children, and 8 of them did not come for follow up. Among the 64, parents of 4 patients complained about dry mouth and slight epistaxis but had overcome the adversities without any medical aid. 5 patients aged 3-7 years had problems using INS due to sneezing and cough followed by the use of spray, but they ultimately completed the course. (Table 2) On table 3 before and after treatment survey of OSA-18 is shown. A significant improvement (p<0.001) is seen as the average total score from 60.95 to 46.37. All the parents informed that there was significant improvement in sleep pattern and physical symptoms which is evident by the scores 15.09 to 11.53 and 13.00 to 9.76 respectively. In all the domains of OSA-18 showed improvements of the course which is demonstrated by a bar chart, except in one domain that is discipline, which was not that significant. Following the INS spray treatment, frequent URI (upper respiratory infection) also improved markedly with the average score 3.54 to 2.61. Emotional distress reducing from 10.12 to 8.76, overall parents' feedback was positive and appreciative for the non-surgical approach. 
Discussion
Adenoid Hypertrophy (AH) leads to different clinical manifestations according to adenoid size. Bilateral nasal obstruction being a primary complaint, a varying sleep disorders are often described, ranging from snoring to OSAS 9 . And so in the pediatric age group AH is considered as one of the most frequent pathologic condition.
Being the secondary lymphoid organ, part of the mucosa-associated lymphoid tissue (MALT), adenoid presents immune activity mainly between 4 and 10 years of age 10 . But in complications such as intermittent sleep, sleepwalking, morning headaches, difficulty concentrating, sleepiness, enuresis, slow feeding, and poor growth due to palatine tonsillar hypertrophy associated with AH, patients are often suggested for surgery as the definitive treatment 11 . Even though adenotonsiliectomy is one of the commonest preferred procedure for childhood hypertrophy, Paulussen et al 12 hypothesized that the removal of adenoid lymphatic tissue could have a negative impact on the systemic immunologic system. Faramarzi et al 13 reported their concern over the true impact of adenotonsillectomy over pediatric immune system. Moreover, it is well demonstrated that adenoids may recur after surgery in 10% to 20% of cases 14-15 . Thus alternate non surgical approaches are well sought and topical nasal steroids were proposed by many authors from the past decade [16] [17] [18] [19] . Chadha and Zhangs 20 review on seven studies demonstrated significant efficacy of various nasal steroids in reducing adenoid size and in improving nasal obstruction symptoms, as measured with fiber-optic nasopharyngeal endoscopy and symptom scores, respectively.
In order to evaluate the alternative non-surgical treatment options, we used intranasal fluticasone furoate in children with adenoid hypertrophy as the data on Bangladeshi population is limited. The treatment was safe and well-tolerated with few minor adverse events. The OSA 18 questionnaire was used to evaluate the effects which are a standard protocol for quality of life evaluation.
The OSA-18 is an 18-item questionnaire that uses a Likert-type scoring system to collect information about 5 sub-scales that are considered to be elements in quality of life: sleep disturbance, physical symptoms, emotional symptoms, daytime function, and caregiver concerns. 21 On the basis of this information, a summary score is calculated that ranges from 18 (no impact on quality of life) to 126 (major negative impact). A value at or above 60 is considered abnormal. 22 The results were found to be in correspondence with the study done in India by Vipan Gupta et al 23 with similar methodology with mometasone furoate. We chose Fluticasone furoate among many other commercially available steroid nasal sprays(beclomethasone propionate, budesonide, flunisolide, mometasone furoate, and triamcinolone acetonide) for mainly 4 reasons.(1) It is generally well tolerated, with types of side effects that are typical of INS class of medicine 24 , (2) It has no effects on the hypothalamic-pituitary-adrenal axis 25 , (3) the systemic availability of the drug after topical administration is lower than that of other steroids 26 and (4) it has no effects on growth in children 27 .
The study of Brouillette et al 17 on 2001 on the efficacy of intranasal steroid treatment for OSAS in a randomized, triple-blind, placebo-controlled, parallel-group trial, investigating the use of fluticasone propionate nasal spray versus placebo for 25 children affected by OSAS revealed improvements in symptom scores in 69% of children. In another study of Hasan Demirhan et al 28 , after 8 weeks of treatment by Fluticasone propionate nasal drops,average total symptoms score dropped from 13.7 to 2.9. And this is well in accordance with our present study.
Conclusions
Treatment with nasal steroids can relief the symptoms of adenoidal hypertrophy and decrease the volume of adenoid. In this study, the effect of fluticasone furoate nasal spray on adenoid hypertrophy is evaluated for the first time. This method provides available alternative to surgical treatment in children with adenoid hypertrophy. But further long term treatment plan and observations (>1year) are essential to support the use of nasal steroids as a first-line approach in children.
